吉非替尼治疗非小细胞肺癌进展
Progress of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2021.1112913, PDF,  被引量    国家自然科学基金支持
作者: 达德转, 李林俞, 李红玲*：甘肃中医药大学第一临床医学院(甘肃省人民医院)，甘肃 兰州；潘志昂：宁夏医科大学，宁夏 银川
关键词: 吉非替尼；非小细胞肺癌(NSCLC)；耐药机制；Gefitinib； Non-Small Cell Lung Cancer (NSCLC)； Resistance Mechanisms
摘要: 在世界范围内恶性肿瘤中死亡率最高的是肺癌，其中非小细胞肺癌(NSCLC)占80%以上。而我国是肺癌大国，绝大多数肺癌患者都诊断于中晚期，失去最佳手术机会，中晚期肺癌患者仍以放化疗及分子靶向治疗为主。吉非替尼是用于NSCLC临床治疗的代表性分子靶向药物，然而分子靶向药吉非替尼在临床应用中仍存在耐药现象，严重影响分子靶向药物治疗肺癌患者的疗效。因此探索吉非替尼的耐药机制，寻找耐药的分子标志物对治疗NSCLC有重要意义。本文将对吉非替尼靶向治疗NSCLC的最新进展进行总结。
Abstract: Lung cancer has the highest mortality rate among malignant tumors worldwide, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. While China is a big country with lung cancer, the vast majority of lung cancer patients are diagnosed in the middle and advanced stage, losing the best opportunity for surgery. Patients with middle and advanced stage lung cancer are still mainly treated with radiotherapy and chemotherapy and molecular targeted therapy. Gefitinib is a representative molecular targeted drug used in the clinical treatment of NSCLC. However, drug resistance of the molecular targeted drug still exists in clinical application, which seriously affects the efficacy of molecular targeted drugs in the treatment of lung cancer patients. Therefore, it is of great significance to explore the mechanism of gefitinib resistance and to find the molecular markers of resistance for the treatment of NSCLC. This article will summarize the latest progress of gefitinib targeted therapy for NSCLC.
文章引用：达德转, 潘志昂, 李林俞, 李红玲. 吉非替尼治疗非小细胞肺癌进展[J]. 临床医学进展, 2021, 11(12): 6150-6155. https://doi.org/10.12677/ACM.2021.1112913

参考文献

[1] Kimberly, R.L. and Jemal, D.A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] 兰蓝, 赵飞, 蔡玥, 等. 中国居民2015年恶性肿瘤死亡率流行病学特征分析[J]. 中华流行病学杂志, 2018, 39(1): 32-34.
[3] Bruckl, W.M., Wiest, G.H. and Ficker, J.H. (2010) Current Status of Erlotinib and Gefitinib in Palliative Therapy for NSCLC—Does the EGF-R Mutation State Have Any Significance? Pneumologie, 64, 727-735. [Google Scholar] [CrossRef] [PubMed]
[4] 王利. 表皮生长因子受体抑制剂吉非替尼的研究进展[J]. 安徽医学, 2015, 36(1): 111-114.
[5] 殷成龙, 劳学军. PI3K-AKT-mTOR信号通路的研究进展[J]. 中国医学创新, 2016, 13(1): 145-148.
[6] Han, W.D., et al. (2011) EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells. PLoS ONE, 6, e18691. [Google Scholar] [CrossRef] [PubMed]
[7] Jin, S.-W. (2005) Cellular and Molecular Analyses of Vascular Tube and Lumen Formation in Zebrafish. Development, 132, 5199-5209. [Google Scholar] [CrossRef] [PubMed]
[8] 张乐平, 舒莉萍, 何志旭, 等. 转基因斑马鱼模型吉非替尼抗血管生成作用研究[J]. 中华肿瘤防治杂志, 2019, 26(7): 447-451.
[9] 张亚龙, 尤嘉琮. 非小细胞肺癌EGFR-TKIs耐药分子靶向研究进展[J]. 药品评价, 2015, 12(14): 14-18.
[10] Fiedler, W., Mesters, R., Tinnefeld, H., et al. (2003) A Phase 2 Clinical Study of SU5416 in Patients with Refractory Acute Myeloid Leukemia. Blood, 102, 2763-2767. [Google Scholar] [CrossRef] [PubMed]
[11] Song, X., Fan, P.D., Bantikassegn, A., et al. (2015) ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas. Cancer Research, 75, 1035-1045. [Google Scholar] [CrossRef] 
[12] 王永生. 人肺腺癌吉非替尼获得性耐药株H1975细胞与敏感株PC9细胞miRNA谱表达差异[J]. 中国肿瘤, 2013, 22(9): 743-747.
[13] Hashida, S., Yamamoto, H., Shien, K., et al. (2015) Hsp90 Inhibitor NVPAUY922 Enhances the Radiation Sensitivity of Lung Cancer Cell Lines with Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. Oncology Reports, 33, 1499-1504. [Google Scholar] [CrossRef] [PubMed]
[14] Miyoshi, S., Kato, T., Katayama, H., et al. (2015) A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors with MET Amplification and Epithelial-to-Mesenchymal Transition. OncoTargets and Therapy, 8, 783-787. [Google Scholar] [CrossRef] 
[15] Noro, R., Seike, M., Zou, F., et al. (2015) MET FISH-Positive Status Predicts Short Progression-Free Survival and Overall Survival after Gefitinib Treatment in Lung Adenocarcinoma with EGFR Mutation. BMC Cancer, 15, Article No. 31.
[16] Sun, Z., Liu, H., Luo, C., et al. (2018) Better Outcomes of Modified Myeloablative Conditioning without Antithymocyte Globulin vs. Myeloablative Conditioning in Cord Blood Transplantation for Hematological Malignancies: A Retrospective (Development) and a Prospective (Validation) Study. International Journal of Cancer, 143, 699-708. [Google Scholar] [CrossRef] [PubMed]
[17] 潘跃银．非小细胞肺癌EGFR-TKIs及其获得性耐药机制的研究进展[J]. 中国科学技术大学学报, 2018, 45(10): 785-790, 796.
[18] Jiang, T. and Zhou, C. (2014) Clinical Activity of the Mutant-Selective EGFR Inhibitor AZD9291 in Patients with EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 3, 370-372.
[19] 马浩. miR-187下调ICAMI提高非小细胞肺癌对吉非替尼的敏感性[J]. 中国临床研究, 2019, 32(10): 1337-1341.
[20] 李晨光, 王长利. 非小细胞肺癌EGFR靶向治疗和继发耐药机制的研究进展[J]. 中国肿瘤临床, 2017(23): 1212-1216.
[21] 李媛, 宋丽华. 非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展[J]. 中国肺癌杂志, 2012, 15(2): 106-111.
[22] 陈蕊, 赵达, 王丽娜. 非小细胞肺癌EGFR-TKI耐药机制及治疗策略[J]. 肿瘤防治研究, 2017, 44(3): 225-230.
[23] 李静, 武新虎, 朱锡旭. 非小细胞肺癌EGFR-TKI耐药机制及耐药后治疗策略[J]. 医学研究生学报, 2013, 26(8): 859-863.
[24] Li, D., Shimamura, T., Ji, H., et al. (2007) Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HkI-272 and Rapamycin Combination Therapy. Cancer Cell, 12, 81-93. [Google Scholar] [CrossRef] [PubMed]

为你推荐